Literature DB >> 23325742

Impact of CCR2 and SDF1 polymorphisms on disease progression in HIV-infected subjects in Thailand.

Palanee Ammaranond1, Sayompoo Sanguansitthianan, Poonlaph Phaengchomduan, Chanachai Sae-Lee, Sirimarn Mardkhumchan.   

Abstract

BACKGROUND: The genotypic polymorphisms of CCR5, CCR2, and SDF1 were analyzed to determine their impact as potential confounders with regard to disease progression because of the role that host genetic factors appear to be involved in determining rates of disease progression.
METHODS: Genomic DNA was extracted from Ethylenediaminetetraacetate whole blood using Qiagen DNA extraction kit. The amplification of CCR5, CCR2, and SDF1 genes was performed by PCR.
RESULTS: Two hundred and twenty-one samples were genotyped for the CCR5, CCR2, and SDF1 mutation. Among these, all (100%) were identified as wild type for CCR5. All were then investigated considering the impact on CD4+ T-cell counts. Samples were divided into two groups based on the CD4+ T-cell numbers. It revealed that in the group of CD4+ T-cell counts ≥200 cells/μl, 15 were found for the homozygous for SDF1 gene (3'A/3'A) whereas one was found in the group of CD4+ T-cell counts <200 cells/μl. Homozygosity for the CCR2 polymorphisms (64I/64I) were five in the group of CD4+ T-cell counts ≥200 cells/μl and none were found in the group of CD4+ T-cell counts <200 cells/μl. These results demonstrated that there was a significant association between CD4+ T-cell numbers and CCR2 and SDF1 polymorphisms (P < 0.001).
CONCLUSIONS: The mutation of CCR2 and SDF1 genes showed a significant difference in the distribution of CD4+ T-cell numbers (P < 0.001) whereas mutation of chemokine coreceptor CCR5 was not appeared to be associated with the impact of CD4+ T-cell counts.
© 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23325742      PMCID: PMC6807585          DOI: 10.1002/jcla.21559

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  40 in total

1.  Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study.

Authors:  M W Smith; M Dean; M Carrington; C Winkler; G A Huttley; D A Lomb; J J Goedert; T R O'Brien; L P Jacobson; R Kaslow; S Buchbinder; E Vittinghoff; D Vlahov; K Hoots; M W Hilgartner; S J O'Brien
Journal:  Science       Date:  1997-08-15       Impact factor: 47.728

2.  Distribution of chemokine receptor CCR2 and CCR5 genotypes and their relative contribution to human immunodeficiency virus type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression.

Authors:  Jianming Tang; Brent Shelton; Nina J Makhatadze; Yuting Zhang; Margaret Schaen; Leslie G Louie; James J Goedert; Eric C Seaberg; Joseph B Margolick; John Mellors; Richard A Kaslow
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

3.  CCR2-64I allele is associated with the progression of AIDS in a Han Chinese population.

Authors:  Lidan Xu; Yuandong Qiao; Xuelong Zhang; Haiming Sun; Jingwei Wang; Donglin Sun; Yan Jin; Yang Yu; Feng Chen; Jing Bai; Hong Ling; Kaili Wang; Songbin Fu
Journal:  Mol Biol Rep       Date:  2009-08-08       Impact factor: 2.316

4.  Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data.

Authors:  J P Ioannidis; P S Rosenberg; J J Goedert; L J Ashton; T L Benfield; S P Buchbinder; R A Coutinho; J Eugen-Olsen; T Gallart; T L Katzenstein; L G Kostrikis; H Kuipers; L G Louie; S A Mallal; J B Margolick; O P Martinez; L Meyer; N L Michael; E Operskalski; G Pantaleo; G P Rizzardi; H Schuitemaker; H W Sheppard; G J Stewart; I D Theodorou; H Ullum; E Vicenzi; D Vlahov; D Wilkinson; C Workman; J F Zagury; T R O'Brien
Journal:  Ann Intern Med       Date:  2001-11-06       Impact factor: 25.391

5.  Global distribution of the CCR2-64I/CCR5-59653T HIV-1 disease-protective haplotype.

Authors:  J J Martinson; L Hong; R Karanicolas; J P Moore; L G Kostrikis
Journal:  AIDS       Date:  2000-03-31       Impact factor: 4.177

6.  Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC)

Authors:  C Winkler; W Modi; M W Smith; G W Nelson; X Wu; M Carrington; M Dean; T Honjo; K Tashiro; D Yabe; S Buchbinder; E Vittinghoff; J J Goedert; T R O'Brien; L P Jacobson; R Detels; S Donfield; A Willoughby; E Gomperts; D Vlahov; J Phair; S J O'Brien
Journal:  Science       Date:  1998-01-16       Impact factor: 47.728

7.  A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation.

Authors:  L G Kostrikis; Y Huang; J P Moore; S M Wolinsky; L Zhang; Y Guo; L Deutsch; J Phair; A U Neumann; D D Ho
Journal:  Nat Med       Date:  1998-03       Impact factor: 53.440

8.  HIV infection and host genetic mutation among injecting drug-users of northeastern states of India.

Authors:  Kamalesh Sarkar; Santa Sabuj Das; Reshmi Pal; Baishali Bal; P Madhusudan; Sekhar Chakraborti
Journal:  J Health Popul Nutr       Date:  2010-04       Impact factor: 2.000

9.  Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection.

Authors:  Stephanie A Mulherin; Thomas R O'Brien; John P Ioannidis; James J Goedert; Susan P Buchbinder; Roel A Coutinho; Beth D Jamieson; Laurence Meyer; Nelson L Michael; Giuseppe Pantaleo; G Paolo Rizzardi; Hanneke Schuitemaker; Haynes W Sheppard; Ioannis D Theodorou; David Vlahov; Philip S Rosenberg
Journal:  AIDS       Date:  2003-02-14       Impact factor: 4.177

10.  Sequence variants of chemokine receptor genes and susceptibility to HIV-1 infection.

Authors:  M Parczewski; M Leszczyszyn-Pynka; M Kaczmarczyk; G Adler; A Binczak-Kuleta; B Loniewska; A Boron-Kaczmarska; A Ciechanowicz
Journal:  J Appl Genet       Date:  2009       Impact factor: 2.653

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.